Pharmacogenomics of statin response
- 1 August 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Lipidology
- Vol. 18 (4), 409-414
- https://doi.org/10.1097/mol.0b013e328235a5a2
Abstract
Statins are widely prescribed and are established as first-line therapy for the primary and secondary prevention of coronary artery disease. However, the benefit of treatment varies between patients. Genetic variation can contribute to interindividual variations in clinical efficacy of drug therapy, and significant progress has been made in identifying common genetic polymorphisms that influence responsiveness to statin therapy. To date, >30 candidate genes related to pharmacokinetics and pharmacodynamics of statins have been investigated as potential determinants of drug responsiveness in terms of low-density lipoprotein cholesterol lowering. Genetic variation at gene loci that affect intestinal cholesterol absorption include apolipoprotein (apo) E; adenosine triphosphate–binding cassette transporter G5 and G8; cholesterol production, such as 3-hydroxy-3-methylglutaryl coenzyme A reductase; and lipoprotein catabolism, such as apoB and the low-density lipoprotein receptor, all may play a role in modulating responsivesness as well genes involved in metabolism of statins such as cytochrome P450. However, there is considerable variation in results reported, and the data suggest that combined analysis of multiple genetic variants in several genes, all of which have possible functional significance, is more likely to give significant results than single gene studies in small sample populations. In the future, pharmacogenomic studies with a greater number of participants (>2,000 participants) should provide a better picture as to who is most likely and who is least likely to benefit from statin therapy.Keywords
This publication has 37 references indexed in Scilit:
- Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatinPharmacological Research, 2007
- The Effect of Apolipoprotein E Polymorphism on the Response to Lipid-Lowering Treatment With Atorvastatin or FenofibrateJournal of Cardiovascular Pharmacology and Therapeutics, 2006
- Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapyJournal of Human Genetics, 2006
- Apoliprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)Acta Cardiologica, 2006
- Apolipoprotein E genotype affects the response to lipid‐lowering therapy in Chinese patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Statins and Risk of Coronary Heart DiseasePublished by American Medical Association (AMA) ,2000